Identification of Proteomic Signatures Associated With Global and Domain Specific Disease Activity in SLE and Their Modulation by Deucravacitinib in a Phase 2 Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2208; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • P2 data • Inflammatory Arthritis
|